FDA Fast-Tracks Psilocybin and Methylone With New Priority Review Vouchers
A White House executive order cut FDA review timelines for psychedelic Breakthrough Therapies from up to 12 months to 1-2 months
FDA Fast-Tracks Psilocybin and Methylone With New Priority Review Vouchers
A White House executive order signed in April 2026 authorized the FDA Commissioner to issue National Priority Vouchers for psychedelic compounds that have received Breakthrough Therapy designation — cutting review timelines from the typical 6 to 12 months down to 1 to 2 months.
Three companies immediately received vouchers: Usona Institute (psilocybin for major depressive disorder), Helus Pharma (psilocin, the active form psilocybin converts to in the body, also for MDD), and Transcend Therapeutics (methylone, a compound similar to MDMA, for severe PTSD). Methylone received breakthrough designation after a Phase 2 trial showed “rapid, robust, and durable improvements” in participants with severe PTSD. Transcend recently initiated Phase 3 trials.
The acceleration comes after Lykos Therapeutics (formerly MAPS PBC) received an FDA Complete Response Letter for MDMA-assisted therapy for PTSD in 2024, citing concerns about trial design and the difficulty of blinding participants to an active psychedelic. The new pathway suggests the administration has chosen to move forward with the category through a different regulatory mechanism rather than relitigating the Lykos decision.
Psilocybin, MDMA-class compounds, and ibogaine are each now in late-stage clinical development, with approval for at least one indication potentially achievable within 1 to 3 years. Texas has passed legislation actively encouraging FDA to advance approval.
Why This Matters for People in Recovery
Approximately 48.5 million Americans have a substance use disorder, and many also carry untreated PTSD and treatment-resistant depression — conditions that both complicate recovery and increase relapse risk. Psychedelic-assisted therapy, if approved, would represent the first genuinely new mechanism for treating these conditions in decades. Rize Recovery tracks emerging treatment options as they move toward availability. Learn more about treatment options.
Sources Cited
- 01.B
- 02.BPsychedelic treatments on the verge of FDA approvalHouston Public Media
Filed Under
sciencepolicyPsilocybinMDMAFDA
Continue reading
More from this section
The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction
Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.
Science & MedicineFrance Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.
France’s ANSM became the first national regulator anywhere to authorize IV racemic ketamine for adult acute suicidal crisis. The US approved esketamine in 2019 but won’t standardize IV ketamine—because it’s a generic with no commercial sponsor.
Science & MedicineThe FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.
DemeRx received FDA IND clearance for noribogaine—an ibogaine metabolite—for alcohol use disorder. Dr. Deborah Mash has been waiting three decades for this regulatory opening.